AMRI Awarded Development and Manufacture Contract from the UK Government

ALBANY, New York, Sept. 30, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that its wholly owned subsidiary, Albany Molecular Research (UK) Ltd., located in Holywell, Wales, United Kingdom, has been awarded a seven-year contract  for the development and manufacture of an active ingredient under clinical evaluation. The contract was awarded by the Defense Science and Technology Laboratory (Dstl), acting on behalf of the United Kingdom's Secretary of State for Defence, the Department of National Defence of Canada and Minister of Defence of the Kingdom of the Netherlands.

AMRI will initially work on the development and scale-up of the investigational drug, and subsequently the manufacture and supply for use during phase 1 clinical trials. If the trials are successful, AMRI will be in a strong position to become the commercial manufacturer of the product for distribution to the government partners of this contract including the United Kingdom, Netherlands and Canada.

"We are excited for the opportunity to work on this important project for the UK government," said AMRI's President and CEO, Thomas E. D'Ambra, Ph.D. "Government contracts and related collaborations outside of our typical outsourcing contracts with biotechnology and pharmaceutical companies are part of our strategy to diversify our revenue base while making our high-quality services available to all industries, sectors and organizations that can benefit from our strengths in discovery, development and manufacturing."

This collaboration underscores AMRI's expertise in providing SMARTSOURCING™ solutions to government agencies working to solve critical health issues. This includes work as both a contractor and subcontractor for various agencies of the U.S. government. AMRI has been a subcontractor in the manufacturing arena for the U.S. Department of Defense for more than a decade. In August 2011, AMRI received a federal contract award from the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network (BPN). This five-year contract provides AMRI with funding of up to $43 million, based on the number of approved projects and availability of funds.

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING^™, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at http://www.amriglobal.com/ or follow us on Twitter (@amriglobal).

About Albany Molecular Research (UK) Ltd.
Albany Molecular Research (UK) Ltd., a wholly owned subsidiary of AMRI, provides development and manufacturing services, including pre-clinical and Phase I – III product development, as well as commercial manufacturing for approved products. The 14-acre site is located about 60 miles outside of Manchester, England and contains Kilo lab, pilot plant and large-scale manufacturing capabilities. In 2012, the site received a Good Manufacturing Practice (GMP) certificate from the Medicines and Healthcare Regulatory Agency (MHRA) of the UK government for AMRI's manufacturing facility in Holywell, Wales, UK, underscoring the quality of the facility and its growth potential.